Oral dexamethasone for the prevention of acute migraine recurrence in pediatric patients presenting to the emergency department with migraine
Cephalalgia Reports · 2018
DOI: 10.1177/2515816318804158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia Reports, 2018. Verfasst von Serena L Orr und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Physicians’ Services Incorporated Foundation.
Abstract (Originalsprache)
Objective
To assess the feasibility of a randomized controlled trial protocol that aims to determine the efficacy and safety of oral dexamethasone compared to placebo for the prevention of migraine recurrence in children and adolescents visiting the pediatric emergency department (ED) with migraine.
Methods
This study was a two-arm, parallel-group, randomized, placebo-controlled, double-blind pilot trial of patients presenting to the pediatric ED with migraine. Eligible participants were randomized at 1:1 ratio to receive either oral dexamethasone 0.6 mg/kg (maximum 15 mg) or matched placebo as a single dose. Efficacy and safety outcomes were assessed at discharge, 48 h and 7 days after discharge. The primary outcome of the trial was feasibility and was assessed through participant recruitment rate, follow-up completion rates, participant satisfaction ratings and comparison of enrolled versus non-enrolled participants. Efficacy and safety outcomes were not analyzed given that this was a pilot study.
Results
Twelve participants were enrolled over the 6-month recruitment period. This represents 60% of the planned sample size and a 10.5% recruitment rate. No other feasibility issues were identified and patients expressed high satisfaction rates with their treatment: 90.9% were satisfied with their treatment at discharge and at 48-h follow-up and 81.8% were satisfied with their treatment at 7-day follow-up (81.8%). There were no significant differences observed when comparing enrolled participants to those not enrolled.
Conclusion
This pilot randomized controlled trial is the first to assess dexamethasone in the pediatric ED for the prevention of migraine recurrence. The protocol is feasible but recruitment in a single center was lower than expected. Future pediatric ED migraine studies may use innovative or pragmatic trial designs to maximize feasibility from a recruitment standpoint.
Förderung
- Physicians’ Services Incorporated Foundation
Zitieren
APA
Orr, S. L., Richer, L., Barrowman, N., & Zemek, R. (2018). Oral dexamethasone for the prevention of acute migraine recurrence in pediatric patients presenting to the emergency department with migraine. Cephalalgia Reports. https://doi.org/10.1177/2515816318804158
Vancouver
Orr SL, Richer L, Barrowman N, Zemek R. Oral dexamethasone for the prevention of acute migraine recurrence in pediatric patients presenting to the emergency department with migraine. Cephalalgia Reports. 2018. doi:10.1177/2515816318804158
BibTeX
@article{Orr2018,
author = {Orr, Serena L and Richer, Lawrence and Barrowman, Nick and Zemek, Roger},
title = {Oral dexamethasone for the prevention of acute migraine recurrence in pediatric patients presenting to the emergency department with migraine},
journal = {Cephalalgia Reports},
year = {2018},
doi = {10.1177/2515816318804158}
}
EUVIMED